Zai Lab (ZLAB) received approval from China's National Medical Products Administration for Tivdak to treat adults with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy, the company said Monday.
The approval was supported by results from a phase 3 trial in which Tivdak showed a 45% reduction in the risk of death compared to chemotherapy in the China subpopulation, Zai Lab said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments